Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CBPO China Biologic Products	$119.99	$119.23	$99.74 ▼ $120.05	$4.72B	0.47	148,695 shs	390,921 shs
IKT Inhibikase Therapeutics	$1.88 +11.6%	$1.77	$1.12 ▼ $4.20	$139.39M	0.9	191,067 shs	109,073 shs
PLX Protalix BioTherapeutics	$1.62 +2.2%	$1.49	$0.89 ▼ $3.10	$128.77M	-0.21	833,837 shs	427,216 shs
PRME Prime Medicine	$3.58 +11.0%	$3.46	$1.11 ▼ $5.17	$482.45M	2.39	2.53 million shs	2.58 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CBPO China Biologic Products	0.00%	0.00%	0.00%	0.00%	0.00%
IKT Inhibikase Therapeutics	0.00%	-1.75%	-12.95%	-5.08%	+15.86%
PLX Protalix BioTherapeutics	+0.64%	+3.95%	0.00%	-2.47%	+62.90%
PRME Prime Medicine	-0.62%	-11.54%	-28.92%	+149.61%	-26.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CBPO China Biologic Products	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	1.7399 of 5 stars	3.3	2.0	0.0	0.0	2.2	0.0	0.6
PLX Protalix BioTherapeutics	3.0621 of 5 stars	3.5	2.0	0.0	0.0	1.9	1.7	1.9
PRME Prime Medicine	2.8974 of 5 stars	3.4	1.0	0.0	0.0	1.8	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CBPO China Biologic Products	0.00	N/A	N/A	N/A
IKT Inhibikase Therapeutics	2.50	Moderate Buy	$6.50	246.67% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$15.00	828.79% Upside
PRME Prime Medicine	2.75	Moderate Buy	$8.92	149.42% Upside

Current Analyst Ratings Breakdown

Latest CBPO, PRME, PLX, and IKT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
7/16/2025	PRME Prime Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$8.00
5/27/2025	PRME Prime Medicine	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$10.00 ➝ $1.50

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CBPO China Biologic Products	$503.70M	9.38	$5.01 per share	23.93	$45.09 per share	2.66
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A
PLX Protalix BioTherapeutics	$61.95M	2.08	$0.09 per share	17.80	$0.47 per share	3.44
PRME Prime Medicine	$4.96M	96.98	N/A	N/A	$1.37 per share	2.61

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CBPO China Biologic Products	$138.81M	$4.28	33.52	27.90	N/A	27.43%	8.32%	7.64%	N/A
IKT Inhibikase Therapeutics	-$19.03M	-$2.67	N/A	N/A	N/A	N/A	-350.63%	-201.82%	N/A
PLX Protalix BioTherapeutics	$8.31M	$0.07	N/A	5.21	N/A	-21.03%	-30.89%	-11.74%	N/A
PRME Prime Medicine	-$198.13M	-$1.56	N/A	N/A	N/A	N/A	-107.87%	-74.97%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CBPO China Biologic Products	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	$1.45	40.45%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CBPO China Biologic Products	N/A	12.01	10.13
IKT Inhibikase Therapeutics	N/A	0.85	0.85
PLX Protalix BioTherapeutics	N/A	1.98	1.27
PRME Prime Medicine	N/A	6.50	6.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CBPO China Biologic Products	34.77%
IKT Inhibikase Therapeutics	3.81%
PLX Protalix BioTherapeutics	16.53%
PRME Prime Medicine	70.37%

Insider Ownership

Company	Insider Ownership
CBPO China Biologic Products	2.73%
IKT Inhibikase Therapeutics	7.30%
PLX Protalix BioTherapeutics	6.50%
PRME Prime Medicine	22.74%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CBPO China Biologic Products	2,269	39.36 million	N/A	Optionable
IKT Inhibikase Therapeutics	6	74.34 million	66.18 million	Not Optionable
PLX Protalix BioTherapeutics	200	79.73 million	69.00 million	Optionable
PRME Prime Medicine	234	134.57 million	100.38 million	Optionable

CBPO, PRME, PLX, and IKT Headlines

Recent News About These Companies

Analysts Set Prime Medicine, Inc. (NYSE:PRME) Target Price at $8.92

August 21 at 2:18 AM | americanbankingnews.com

Positive Signs As Multiple Insiders Buy Prime Medicine Stock

August 20 at 7:34 AM | uk.finance.yahoo.com

Prime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of "Moderate Buy" by Analysts

August 19 at 3:50 AM | marketbeat.com

Analysts Set Expectations for Prime Medicine FY2025 Earnings

August 16, 2025 | marketbeat.com

Q3 EPS Estimates for Prime Medicine Cut by HC Wainwright

August 16, 2025 | marketbeat.com

HC Wainwright Cuts Earnings Estimates for Prime Medicine

August 16, 2025 | americanbankingnews.com

Chardan Capital Lowers Prime Medicine (NYSE:PRME) Price Target to $10.00

August 10, 2025 | marketbeat.com

Prime Medicine, Inc.: Strong Buy Rating Backed by Promising Pipeline and Robust Financial Position

August 8, 2025 | tipranks.com

PRME Revenue Misses by 73%

August 8, 2025 | aol.comA

Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates

August 7, 2025 | zacks.com

Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 7, 2025 | globenewswire.com

Prime Medicine (NYSE:PRME) Trading Down 6.7% - Here's What Happened

August 6, 2025 | marketbeat.com

Prime Medicine Holds Special Stockholder Meeting

August 5, 2025 | tipranks.com

Prime Medicine (NYSE:PRME) Shares Gap Up on Insider Buying Activity

August 5, 2025 | marketbeat.com

Friday’s Insider Trades: Key Buys and Sells in US Stocks Revealed

August 4, 2025 | investing.com

Arch Venture Partners Xii, Llc Purchases 3,030,300 Shares of Prime Medicine, Inc. (NYSE:PRME) Stock

August 2, 2025 | marketbeat.com

Prime Medicine, Inc. (NYSE:PRME) Major Shareholder Arch Venture Partners Xii, Llc Purchases 3,030,300 Shares

August 2, 2025 | insidertrades.com

Prime Medicine Halts Sales Agreement Prospectus

August 1, 2025 | theglobeandmail.com

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

August 1, 2025 | finance.yahoo.com

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

August 1, 2025 | globenewswire.com

Prime Medicine (NYSE:PRME) Shares Gap Down - Here's Why

August 1, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBPO, PRME, PLX, and IKT Company Descriptions

China Biologic Products NASDAQ:CBPO

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, auto-immune deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.

Inhibikase Therapeutics NYSE:IKT

$1.88 +0.20 (+11.61%)

As of 03:35 PM Eastern

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Protalix BioTherapeutics NYSE:PLX

$1.62 +0.04 (+2.22%)

As of 03:36 PM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Prime Medicine NYSE:PRME

$3.58 +0.36 (+11.02%)

As of 03:36 PM Eastern

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time